We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MBT:PSEMetropolitan Bank & Trust Co. Analysis

Data as of 2026-07-19 - not real-time

IDR 120.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading well below its long‑term moving average, signaling a bearish backdrop. The 20‑day and 50‑day simple moving averages sit under the current price, offering modest near‑term support. However, the 200‑day average remains far higher, underscoring a dominant downtrend. Momentum indicators show the RSI in the upper‑mid zone, indicating still‑present buying pressure. The MACD histogram is positive and the signal line is bullish, hinting at a possible short‑term rebound. Volume has been climbing, which can provide the liquidity needed for a bounce.
On the fundamentals side, earnings are negative and margins are thin, while debt levels are high relative to equity. The price‑to‑book ratio is well under one, and the discounted cash‑flow model suggests a valuation many times the market price. Cash generation from operations is solid, but free cash flow is modest compared with the debt burden. The company operates in the consumer‑defensive sector, which tends to be less cyclical but still faces regulatory scrutiny in cosmetics and herbal products. The high recent volatility and a beta above one point to an elevated risk profile. Overall, the stock appears deeply discounted but carries significant upside risk if the business can reverse its earnings trend.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • dominant bearish long‑term trend
  • price near technical support
  • elevated volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • deep discount to DCF valuation
  • strong operating cash flow
  • low price‑to‑book ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • potential earnings turnaround
  • growth opportunities in cosmetics and herbal segments
  • significant upside implied by valuation gap

Key Metrics & Analysis

Financial Health

Revenue Growth23.90%
Profit Margin-3.13%
ROE-3.74%
ROA1.16%
Debt/Equity45.55
P/B Ratio0.4
Op. Cash FlowIDR30.2B
Free Cash FlowIDR30.6B

Technical Analysis

TrendBearish
RSI63.6
SupportIDR 91.00
ResistanceIDR 138.00
MA 20IDR 108.00
MA 50IDR 110.08
MA 200IDR 148.18
MACDBullish
VolumeIncreasing
Fear & Greed Index87.91

Valuation

Fair ValueIDR 837.22
GradeUndervalued
TypeValue

Risk Assessment

Beta1.12
Volatility65.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.